{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:54Z","timestamp":1793744694958,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2023.116098","type":"journal-article","created":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T06:27:10Z","timestamp":1704090430000},"page":"116098","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model"],"prefix":"10.1016","volume":"265","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7227-0921","authenticated-orcid":false,"given":"Jean M.","family":"Delabar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Ant\u00f4nio G.B.","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fructuoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Sarrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Fleary-Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Chi","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodrigues-Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Janel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dairou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmilson J.","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Claude","family":"Potier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.116098_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.pharmthera.2018.09.010","article-title":"DYRK1A and cognition: a lifelong relationship","volume":"194","author":"Arbones","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2023.116098_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000472398","article-title":"Molecular mapping of twenty-four features of Down syndrome on chromosome 21","volume":"1","author":"Delabar","year":"1993","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2023.116098_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.gene.2013.11.078","article-title":"A patient with partial trisomy 21 and 7q deletion expresses mild Down syndrome phenotype","volume":"536","author":"Papoulidis","year":"2014","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2023.116098_bib4","doi-asserted-by":"crossref","first-page":"5958","DOI":"10.1073\/pnas.86.15.5958","article-title":"Critical role of the D21S55 region on chromosome 21 in the pathogenesis of Down syndrome","volume":"86","author":"Rahmani","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2023.116098_bib5","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/jmg.2006.047373","article-title":"Familial 4.3 Mb duplication of 21q22 sheds new light on the Down syndrome critical region","volume":"44","author":"Ronan","year":"2007","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ejmech.2023.116098_bib6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1242\/dmm.029728","article-title":"Rodent models in Down syndrome research: impact and future opportunities","volume":"10","author":"Herault","year":"2017","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejmech.2023.116098_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2012.01.007","article-title":"DYRK1A: a master regulatory protein controlling brain growth","volume":"46","author":"Guedj","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.116098_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.nbd.2014.04.016","article-title":"Excitation\/inhibition balance and learning are modified by Dyrk1a gene dosage","volume":"69","author":"Souchet","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.116098_bib9","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nbd.2005.03.020","article-title":"Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models","volume":"20","author":"Ferrer","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.116098_bib10","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/hmg\/ddl437","article-title":"The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease","volume":"16","author":"Kimura","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2023.116098_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22116047","article-title":"Dual-specificity, tyrosine phosphorylation-regulated kinases (DYRKs) and cdc2-like kinases (CLKs) in human disease, an overview","volume":"22","author":"Lindberg","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116098_bib12","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0960-894X(02)00094-X","article-title":"Beta-carbolines as specific inhibitors of cyclin-dependent kinases","volume":"12","author":"Song","year":"2002","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.116098_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021535","article-title":"The specificities of protein kinase inhibitors: an update","volume":"371","author":"Bain","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2023.116098_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114062","article-title":"DYRK1A inhibitors for disease therapy: current status and perspectives","volume":"229","author":"Liu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2023.116098_bib16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2016.04.004","article-title":"Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: design, synthesis, inhibitory potency and X-ray co-crystal structure","volume":"118","author":"Esvan","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib17","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2018.08.097","article-title":"Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: identification of the cyclopropylamide moiety as a key modification","volume":"158","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ejmech.2018.08.007","article-title":"Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic beta-cell proliferation activity","volume":"157","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib19","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejmech.2018.07.050","article-title":"Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives","volume":"157","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2019.01.052","article-title":"New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis","volume":"166","author":"Tazarki","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113554","article-title":"Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3beta\/DYRK1A dual inhibitors for the treatment of Alzheimer's disease","volume":"222","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113911","article-title":"Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A\/alpha-synuclein aggregation inhibitors with neuroprotective effects","volume":"227","author":"AlNajjar","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114054","article-title":"ARN25068, a versatile starting point towards triple GSK-3beta\/FYN\/DYRK1A inhibitors to tackle tau-related neurological disorders","volume":"229","author":"Demuro","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib24","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1021\/acs.jmedchem.2c02068","article-title":"Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases","volume":"66","author":"Lindberg","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.128226","article-title":"Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A\/1B inhibitors","volume":"47","author":"Park","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2023.116098_bib26","doi-asserted-by":"crossref","first-page":"9569","DOI":"10.1021\/jm401049v","article-title":"Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity","volume":"56","author":"Gourdain","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib27","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41598-018-20984-z","article-title":"DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives","volume":"8","author":"Neumann","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116098_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3389\/fnbeh.2015.00267","article-title":"Pharmacological correction of excitation\/inhibition imbalance in Down syndrome mouse models","volume":"9","author":"Souchet","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.ejmech.2023.116098_bib29","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.nut.2009.11.022","article-title":"Protective effect of green tea (-)-epigallocatechin-3-gallate against the monoamine oxidase B enzyme activity increase in adult rat brains","volume":"26","author":"Lin","year":"2010","journal-title":"Nutrition"},{"key":"10.1016\/j.ejmech.2023.116098_bib30","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1021\/bi060632j","article-title":"Kinetic properties of a MNB\/DYRK1A mutant suitable for the elucidation of biochemical pathways","volume":"45","author":"Adayev","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2023.116098_bib31","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.bbrc.2006.10.169","article-title":"MNB\/DYRK1A phosphorylation regulates the interactions of synaptojanin 1 with endocytic accessory proteins","volume":"351","author":"Adayev","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2023.116098_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004606","article-title":"Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A","volume":"4","author":"Guedj","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.116098_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041404","article-title":"Molecular rescue of Dyrk1A overexpression alterations in mice with fontup((R)) dietary supplement: role of green tea catechins","volume":"21","author":"Gu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2023.116098_bib34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.phrs.2011.02.007","article-title":"The chemistry and biotransformation of tea constituents","volume":"64","author":"Sang","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2023.116098_bib35","doi-asserted-by":"crossref","first-page":"7887","DOI":"10.1021\/acs.jafc.2c02527","article-title":"Redox and other biological activities of tea catechins that may affect health: mechanisms and unresolved issues","volume":"70","author":"Yang","year":"2022","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib36","doi-asserted-by":"crossref","first-page":"12254","DOI":"10.1039\/D1RA01480C","article-title":"Medicinal chemistry perspectives of 1,2,3,4-tetrahydroisoquinoline analogs - biological activities and SAR studies","volume":"11","author":"Faheem","year":"2021","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2023.116098_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/1475-2875-10-348","article-title":"Broad inhibition of plasmodium falciparum cytoadherence by (+)-epigallocatechin gallate","volume":"10","author":"Patil","year":"2011","journal-title":"Malar. J."},{"key":"10.1016\/j.ejmech.2023.116098_bib38","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1248\/cpb.25.2838","article-title":"Polycyclic N-hetero compounds. XV. The vilsmeier reaction of phenylacetonitriles. II","volume":"25","author":"Hirota","year":"1977","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2023.116098_bib39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1248\/cpb.23.497","article-title":"Polycyclic N-hetero compounds. V. A novel synthesis of isoquinoline by the vilsmeier reaction of phenylacetonitriles","volume":"23","author":"Koyama","year":"1975","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2023.116098_bib40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/157017807780414217","article-title":"New synthesis of 3-aryl isoquinolines by Pd-catalyzed Suzuki cross-coupling","volume":"4","author":"Franceschin","year":"2007","journal-title":"Lett. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib41","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1002\/ejoc.201400090","article-title":"Selective suzuki\u2013miyaura monocouplings with symmetrical dibromoarenes and aryl ditriflates for the one-pot synthesis of unsymmetrical triaryls","volume":"2014","author":"Minard","year":"2014","journal-title":"Eur. J. Org. Chem."},{"key":"10.1016\/j.ejmech.2023.116098_bib42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ab.2013.12.024","article-title":"A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase","volume":"449","author":"Bui","year":"2014","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2023.116098_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans","volume":"58","author":"De la Torre","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2023.116098_bib44","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1474-4422(16)30034-5","article-title":"Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"15","author":"de la Torre","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2023.116098_bib45","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1093\/hmg\/ddq179","article-title":"A mouse model of Down syndrome trisomic for all human chromosome 21 syntenic regions","volume":"19","author":"Yu","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2023.116098_bib46","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1038\/s41598-019-40328-9","article-title":"Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models","volume":"9","author":"Souchet","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2023.116098_bib47","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1080\/09297049.2013.856396","article-title":"Memory coding in individuals with Down syndrome","volume":"20","author":"Lanfranchi","year":"2014","journal-title":"Child Neuropsychol."},{"key":"10.1016\/j.ejmech.2023.116098_bib48","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1523\/JNEUROSCI.1547-09.2009","article-title":"The \"Down syndrome critical region\" is sufficient in the mouse model to confer behavioral, neurophysiological, and synaptic phenotypes characteristic of Down syndrome","volume":"29","author":"Belichenko","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2023.116098_bib49","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.nbd.2011.04.011","article-title":"Comprehensive behavioral phenotyping of Ts65Dn mouse model of Down syndrome: activation of beta1-adrenergic receptor by xamoterol as a potential cognitive enhancer","volume":"43","author":"Faizi","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2023.116098_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1037\/0735-7044.108.5.883","article-title":"Working memory, response selection, and effortful processing in rats with medial prefrontal lesions","volume":"108","author":"Granon","year":"1994","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.ejmech.2023.116098_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106572","article-title":"Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome","volume":"9","author":"Garcia-Cerro","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2023.116098_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030443","article-title":"Development of novel fluorinated polyphenols as selective inhibitors of DYRK1A\/B kinase for treatment of neuroinflammatory diseases including Parkinson's disease","volume":"16","author":"Araldi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2023.116098_bib53","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1021\/jf204497b","article-title":"Epicatechin-3-O-(3''-O-methyl)-gallate content in various tea cultivars (Camellia sinensis L.) and its in vitro inhibitory effect on histamine release","volume":"60","author":"Maeda-Yamamoto","year":"2012","journal-title":"J. Agric. Food Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423010656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423010656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:54:39Z","timestamp":1736866479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423010656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":53,"alternative-id":["S0223523423010656"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116098","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.116098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116098"}}